|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-3-18
|
|
pubmed:abstractText |
Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor. Pharmacokinetic properties of candesartan explain its pronounced and lengthy (24-36 hours) antihypertensive action which does not depend on patients sex, age and body mass. Long term use of candesartan has been associated with regression of left ventricular hypertrophy, renoprotective effect and lowered risk of stroke. Candesartan is well tolerated. All these features make the drug suitable for wide application in the management of hypertension. Preliminary results suggest that candesartan can be useful in the treatment of diabetic nephropathy.
|
|
pubmed:language |
rus
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acrylates,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/EXP3174,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes,
http://linkedlifedata.com/resource/pubmed/chemical/Valine,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan,
http://linkedlifedata.com/resource/pubmed/chemical/eprosartan,
http://linkedlifedata.com/resource/pubmed/chemical/irbesartan,
http://linkedlifedata.com/resource/pubmed/chemical/valsartan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0022-9040
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
55-65
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15029149-Acrylates,
pubmed-meshheading:15029149-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:15029149-Antihypertensive Agents,
pubmed-meshheading:15029149-Benzimidazoles,
pubmed-meshheading:15029149-Biphenyl Compounds,
pubmed-meshheading:15029149-Diabetic Nephropathies,
pubmed-meshheading:15029149-Humans,
pubmed-meshheading:15029149-Hypertension,
pubmed-meshheading:15029149-Imidazoles,
pubmed-meshheading:15029149-Tetrazoles,
pubmed-meshheading:15029149-Thiophenes,
pubmed-meshheading:15029149-Valine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
|
|
pubmed:affiliation |
Presidential Medical Center of Russia; ul. Marshala Timoschenko 15, 121356 Moscow, Russia.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|
